The U.S. Food and Drug Administration (FDA) has announced a shortage of long-acting penicillin G benzathine injectable suspension products (Bicillin L-A), with an estimated recovery not before spring of 2024. Per the FDA, this drug shortage is due to an increased demand for the drug. Given the high rates of syphilis in California and in Santa Clara County, this is of significant concern.
Bicillin L-A remains the only acceptable treatment for pregnant people infected with or exposed to syphilis and should be prioritized for this population to prevent the harmful effects of congenital syphilis, including premature birth, low birth weight, birth defects, stillbirth, and infant death.
Acceptable alternative treatments for non-pregnant adults include:
- Primary, Secondary, Early Latent syphilis or exposure to syphilis: Doxycycline 100mg PO BID x 14 days
- Late Latent/ Unknown Duration syphilis: Doxycycline 100mg PO BID x 28 days
Bicillin C-R is not an acceptable alternative for the treatment of syphilis. |
|